Arcutis Biotherapeutics (ARQT) Receivables (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Receivables of $144.4 million for Q1 2026, up 69.03% year-over-year from $85.4 million in Q1 2025, and down 1.27% quarter-over-quarter from $146.2 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Receivables (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Receivables history runs 5 years deep, the most recent figure standing at $144.4 million for Q1 2026.
- In Q1 2026, Receivables rose 69.03% year-over-year to $144.4 million; the TTM figure through Mar 2026 stood at $144.4 million (up 69.03% YoY), while the FY2025 annual figure was $146.2 million, up 100.13% from the prior year.
- Receivables for Q1 2026 stood at $144.4 million, down from $146.2 million in the prior quarter.
- The five-year high for Receivables was $146.2 million in Q4 2025, with the low at $2.4 million in Q3 2022.
- The 5-year median for Receivables is $43.4 million (2024), against an average of $59.8 million.
- The sharpest annual moves came in 2023 and 2026: Receivables soared 698.72% in 2023, then surged 69.03% in 2026.
- Arcutis Biotherapeutics' Receivables stood at $8.5 million in 2022, then surged by 205.12% to $25.8 million in 2023, then soared by 183.12% to $73.1 million in 2024, then jumped by 100.13% to $146.2 million in 2025, then declined by 1.27% to $144.4 million in 2026.
- Business Quant data shows ARQT's Receivables at $144.4 million in Q1 2026, $146.2 million in Q4 2025, and $115.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 155.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 155.16 Mn |
| Mar 31, 2026 | 144.38 Mn |
| Dec 31, 2025 | 146.23 Mn |
| Sep 30, 2025 | 115.12 Mn |
| Jun 30, 2025 | 106.69 Mn |
| Mar 31, 2025 | 85.42 Mn |
| Dec 31, 2024 | 73.07 Mn |
| Sep 30, 2024 | 60.12 Mn |
| Jun 30, 2024 | 43.41 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Dec 31, 2023 | 25.81 Mn |
| Sep 30, 2023 | 19.42 Mn |
| Jun 30, 2023 | 17.21 Mn |
| Mar 31, 2023 | 12.77 Mn |
| Dec 31, 2022 | 8.46 Mn |
| Sep 30, 2022 | 2.43 Mn |